Saving American Lives at the Trump-Xi Summit | Opinion

A recent analysis underscores the urgency for President Trump to prioritize securing China's renewed commitment to combating the U.S. fentanyl crisis during the upcoming summit with President Xi. Despite past U.S.-China cooperation leading to a significant 34% decline in overall overdose deaths and a 46% drop in fentanyl-related fatalities, current counternarcotics efforts have stalled. The piece advocates for Trump to press China on regulating precursor chemicals, disrupting illicit financial networks, and resuming law enforcement collaboration, arguing that failure to act risks reversing critical public health gains and impacting broader bilateral relations.

Analysis

The upcoming Trump-Xi summit on October 30 presents a critical juncture for U.S.-China counternarcotics cooperation, specifically regarding the fentanyl crisis. Previous bilateral efforts, characterized by a two-pronged strategy addressing demand and supply, yielded significant results, including a 34% decline in total U.S. drug overdose deaths from a peak of 111,451 to 73,690, and a preliminary 46% decrease in fentanyl-related fatalities in 2024. This progress was driven by coordinated law enforcement actions, sanctions, and diplomatic pressure on China's chemical industry.

However, this progress has reportedly stalled, with U.S. and Chinese counternarcotics experts ceasing meetings and no new joint criminal cases announced this year. Despite President Trump's campaign rhetoric and the imposition of 20% tariffs on China, the administration's engagement on fentanyl appears limited, with few cabinet officials publicly addressing the issue with their Chinese counterparts. This lack of sustained engagement risks undoing fragile gains and potentially reversing the positive trends in overdose mortality.

The article emphasizes the need for President Trump to leverage the upcoming summit to press China on several fronts. These include regulating unregulated precursor chemicals, disrupting illicit financial networks, dismantling online marketplaces for precursors, and implementing "know-your-customer" rules for its chemical and shipping sectors. Renewed high-level engagement and the restart of regular expert meetings are deemed crucial to advance policy actions and legal investigations.

Key Decisions for Investors

• Monitor U.S.-China bilateral relations closely for shifts in counternarcotics cooperation, as renewed engagement could impact regulatory environments for chemical and logistics sectors.
• Evaluate potential regulatory risks for companies involved in the production or distribution of specialty chemicals, particularly those with supply chain exposure to China, given calls for stricter "know-your-customer" rules and precursor chemical regulations.
• Assess the broader geopolitical landscape for implications on trade and supply chain stability, as the fentanyl issue, if unresolved, could become a point of friction impacting other economic negotiations.